|
1.
|
receiving
the financial statements of the Corporation for the financial year ended
May 31, 2008, including the auditors'
report;
|
|
2.
|
electing
directors;
|
|
3.
|
appointing
KPMG LLP as auditors of the Corporation for the ensuing year and to
authorize the directors to fix the remuneration to be paid to the
auditors; and
|
|
4.
|
to
consider, and if deemed advisable, approve the unallocated options under
the stock option plan.
|
A.
|
Voting
Instruction Form. In most cases, a non-registered holder will receive, as
part of the meeting materials, a voting instruction form. If the
non-registered holder does not wish to attend and vote at the Meeting in
person (or have another person attend and vote on the non-registered
holder's behalf), the voting instruction form must be completed, signed
and returned in accordance with the directions on the form. If a
non-registered holder wishes to attend and vote at the Meeting in person
(or have another person attend and vote on the non-registered holder's
behalf), the non-registered holder must complete, sign and return the
voting instruction form in accordance with the directions provided and a
form of proxy giving the right to attend and vote will be forwarded to the
non-registered holder.
|
B.
|
Form
of Proxy. Less frequently, a non-registered holder will receive, as part
of the meeting materials, a form of proxy that has already been signed by
the intermediary (typically by a facsimile or stamped signature), which is
restricted as to the number of common shares beneficially owned by the
non-registered holder but which is otherwise uncompleted. If the
non-registered holder does not wish to attend and vote at the Meeting in
person (or have another person attend and vote on the non-registered
holder's behalf), the non-registered holder must complete the form of
proxy and deposit it with Computershare, 100 University Avenue, 8th Floor
Toronto, Canada, M5J 2Y1 as described above. If a non-registered
holder wishes to attend and vote at the Meeting in person (or have another
person attend and vote on the non-registered holder's behalf), the
non-registered holder must strike out the names of the persons named in
the proxy and insert the non-registered holder's (or such other person's)
name in the blank space provided.
|
|
Non-registered
holders should follow the instructions on the forms they receive and
contact their intermediaries promptly if they need
assistance.
|
|
(a)
|
completing
and signing a proxy bearing a later date and depositing it with
Computershare as described above;
or
|
|
(b)
|
depositing
an instrument in writing executed by the shareholder or by the
shareholder's attorney authorized in
writing:
|
|
(i)
|
at
our registered office at any time before 10:00 a.m. on Wednesday,
October 1, 2008, or 48 hours (not including Saturdays, Sundays and
holidays) before any adjournment of the Meeting at which the proxy is to
be used, or
|
|
(ii)
|
with
the chair of the Meeting prior to the commencement of the Meeting on the
day of the Meeting or any adjournment of the Meeting;
or
|
|
(c)
|
in
any other manner permitted by law.
|
|
•
|
FOR the election of the
directors nominated for election as listed in this
Circular
|
|
•
|
FOR the appointment of KPMG LLP
as auditors of the
Corporation
|
|
•
|
FOR the approval of the
unallocated options under the stock option plan of the
Corporation
|
|
•
|
Mr.
Buchi has served as chair of the Audit Committee and member of the
Corporate Governance, and Nomination
Committee;
|
|
•
|
Mr. Steigrod
has served as a member of the Audit Committee and Chair of the
Compensation Committee, and
|
|
•
|
Ms.
Koppy has served as a member of the Compensation and Corporate Governance,
and Nomination Committees.
|
Name Of
Director, Province/State
and Country
of Residence
|
Position with the
Corporation and when
Individual became a Director
|
Present Principal Occupation or
Employment
|
No. of common shares
Beneficially Owned,
Controlled
or Directed
|
HERBERT
ABRAMSON(3)
Ontario,
Canada
|
Director
July 2007
|
Chairman,
CEO and Portfolio Manager, Trapeze Capital Corp.
(investment
dealer/portfolio manager)
Chairman
and Portfolio Manager, Trapeze Asset Management Inc.
(investment
counselor)
|
47,101,515
|
DR. DENIS BURGER(1) (2)
Oregon,
United States
|
Director
September 2007
|
Retired,
currently lead independent director of Trinity Biotech plc.
(developer,
manufacturer of clinical diagnostic products)
Chairman
and CEO of AVI BioPharma, Inc. (1992-2007)
(biopharmaceutical
using gene-targeted therapeutics to interfere with ribosomal
translation)
|
59,620
|
GEORG
LUDWIG (4)
Eschen,
Liechtenstein
|
Director
September 2006
|
Managing
Director, ConPharm Anstalt (2005 to present)
(consulting
and managing company for life science funds)
Managing
Director, High Tech Private Equity
(general
partner of High Tech)
(2000
to 2004)
|
36,362,500
|
DR.
MARK D. VINCENT
Ontario,
Canada
|
Director
September 2007
|
Chief
Executive Officer, Sarissa Inc.
(biotechnology
company focused on development of targeted products for the therapeutic
manipulation of gene expression)
|
Nil
|
DR.
JIM A. WRIGHT
Ontario,
Canada
|
Director,
October 1999
|
Chief
Executive Officer of NuQuest Bio Inc. (2006 to present)
(start-up
biotechnology company with the intention of developing novel therapies for
treatment of life threatening diseases)
President
and Chief Executive Officer, Lorus (1999 to 2006)
|
4,639,791
|
DR.
AIPING YOUNG
Ontario,
Canada
|
Director,
President and Chief Executive Officer, October 2006
|
President
and Chief Executive Officer of the Corporation
(2006
to present)
Chief
Operating Officer, Lorus (2003 to 2006)
|
334,153
|
(1)
|
Member
of the Audit Committee.
|
(2)
|
Member
of the Compensation Committee.
|
(3)
|
Member
of the Corporate Governance and Nominating
Committee.
|
(4)
|
Pursuant
to a subscription agreement with High Tech dated July 13, 2006, as
amended, for as long as High Tech owns shares of the Corporation, it is
entitled to put forward a board nominee. Georg Ludwig is the nominee of
High Tech.
|
|
1.
|
the
unallocated options under the stock option plans are approved and
affirmed;
|
|
2.
|
the
Corporation seed further shareholder approval of unallocated options under
the stock option plans no later than October 1, 2011;
and
|
|
3.
|
any
director or officer of the Corporation is hereby authorized and directed
for and in the name of and on behalf of the Corporation to execute, or
cause to be executed, whether under corporate seal of the Corporation or
otherwise, and to deliver or cause to be delivered such certificates,
instruments, agreements, notices and other documents, and to do or cause
to be done all such other acts and things as such director or officer
determines to be necessary or desirable in connection with the foregoing,
such determination to be conclusively evidenced by the execution of such
document, agreement or instrument or the doing of any such act or
filing.
|
Annual Compensation
|
Long-Term
Compensation
Awards
|
|||||
Name and Principal Position
|
Fiscal
Year
|
Salary
($)
|
Bonus
($)
|
Other
Annual
Compensation
($)
|
Securities
Under
Options
/SARs Granted
(#)(1)
|
All
Other
Compensation
($)
|
Dr.
Aiping Young
President
and Chief Executive Officer, former Chief Operating
|
2008
2007
2006
|
323,846
286,269
259,692
|
117,600
41,250
32,000
|
Nil
Nil
Nil
|
1,350,000
2,312,496
1,194,144
|
Nil
Nil
Nil
|
Ms.
Elizabeth Williams(2)
Director
of Finance, Acting Chief Financial Officer
|
2008
2007
2006
|
27,412
87,152
88,631
|
15,996
7,565
7,000
|
Nil
Nil
Nil
|
200,000
139,739
228,035
|
Nil
Nil
Nil
|
Dr.
Saeid Babaei(3)
Vice
President Business Development
|
2008
2007
2006
|
126,606
64,731
Nil
|
10,072
Nil
Nil
|
Nil
Nil
Nil
|
300,000
Nil
Nil
|
Nil
Nil
Nil
|
Dr.
Yoon Lee(4)
Vice
President Research
|
2008
2007
2006
|
116,581
109,752
92,314
|
16,647
7,901
8,413
|
Nil
Nil
Nil
|
300,000
240,833
27,585
|
Nil
Nil
Nil
|
Dr.
Jim A. Wright(5)
Former
President and Chief Executive Officer
|
2008
2007
2006
|
Nil
108,814
345,442
|
Nil
131,070
53,000
|
Nil
Nil
Nil
|
Nil
(265,000)
947,500
|
Nil
584,630
Nil
|
Mr.
Peter Korth(6)
Former
Chief Financial Officer
|
2008
2007
2006
|
48,462
Nil
Nil
|
Nil
Nil
Nil
|
Nil
Nil
Nil
|
250,000
Nil
Nil
|
29,423
Nil
Nil
|
Mr.
Paul Van Damme(7)
Former
Chief Financial Officer
|
2008
2007
2006
|
Nil
Nil
152,654
|
Nil
Nil
35,030
|
Nil
Nil
Nil
|
Nil
Nil
Nil
|
Nil
Nil
74,633
|
(1)
|
Options
granted are net of forfeitures.
|
(2)
|
Ms.
Williams was on maternity leave from February 2007 to January
2008. Ms. Williams returned to work on a part time
basis.
|
(3)
|
Dr.
Babaei started with Lorus on September 7, 2006; hence, there are no
amounts relating to Dr. Babaei’s compensation for 2006. Dr.
Babaei was promoted to Vice President of Business Development on May 5,
2008.
|
(4)
|
Dr.
Lee was promoted to Vice President of Research on May 5,
2008.
|
(5)
|
Dr. Wright
resigned from his position on September 21, 2006. The amount of "All
Other Compensation" relates to a lump sum amount paid pursuant to our
separation agreement with
Dr. Wright.
|
(6)
|
Mr.
Korth resigned from his position on April 14, 2008. The amount
of “All Other Compensation” relates to salary continuance paid pursuant to
our separation agreement with Mr.
Korth.
|
(7)
|
Mr. Van
Damme resigned from his position on November 9, 2005. The amount of
"All Other Compensation" relates to a lump sum amount paid pursuant to our
separation agreement with Mr. Van
Damme.
|
Name and Principal Position
|
Securities
Under Options/SARs Granted
(#)
|
% of Total
Options/SARs Granted to Employees in FinancialYear
(%)
|
Exercise or
Base Price
($/Security)
|
Market Value of Securities Underlying
Options/SARs on the Date of Grant
($/Security)
|
Expiration
Date
|
Dr.
Aiping Young
President
and Chief Executive Officer, Former Chief Operating Officer
|
900,000(2)
450,000(2)
|
16.53
8.27
|
0.205
0.220
|
0.205
0.220
|
January
14, 2018
July
21, 2017
|
Ms.
Elizabeth Williams
Director
of Finance, Acting Chief Financial Officer
|
200,000(1)
|
3.31
|
0.220
|
0.220
|
July
21, 2017
|
Dr.
Saeid Babaei
Vice
President Business Development
|
150,000(1)
150,000(2)
|
2.48
2.48
|
0.220
0.190
|
0.220
0.190
|
July
21, 2017
February
4, 2018
|
Dr.
Yoon Lee
Vice
President Research
|
150,000(1)
150,000(2)
|
2.48
2.48
|
0.220
0.190
|
0.220
0.190
|
July
21, 2017
February
4, 2018
|
Mr.
Peter Korth
Former
Chief Financial Officer
|
250,000(3)
|
4.13
|
0.19
|
0.19
|
January
20, 2018
|
(1)
|
These
options were granted on July 21, 2007 in respect of corporate and
personal performance during the year ended May 31, 2007. The options
vest on the basis of 50% on the first anniversary and 25% on the second
and third anniversaries of the date of
granting.
|
(2)
|
These
options to purchase common shares are incentive options. The options vest
upon the attainment of specific undertakings based on certain corporate
performance objectives; failing to achieve the undertakings will result in
forfeiture on the specified
deadline.
|
(3)
|
Options
granted upon entering into Employment Agreement. The options vested upon
granting.
|
|
Aggregated
Option/SAR Exercises During the Most Recently
Completed
|
Name and Principal Position
|
Securities
Acquired on
Exercise
(#)
|
Aggregate
Value
Realized
($)
|
Unexercised
1)Options/SARs
at
May
31, 2008
(#)
Exercisable/
Unexercisable
|
Value
of Unexercised
in-the-Money
Options/SARs
at
May
31, 2008 ($)
Exercisable/
Unexercisable
|
Dr.
Aiping Young
President
and Chief Executive Officer,
Former
Chief Operating Officer
|
Nil
|
Nil
|
4,747,442/1,100,000
|
0/0
|
Ms.
Elizabeth Williams
Director
of Finance, Acting Chief Financial Officer
|
Nil
|
Nil
|
288,257/331,906
|
0/0
|
Dr.
Saeid Babaei
Vice
President Business Development
|
Nil
|
Nil
|
150,000/150,000
|
0/0
|
Dr.
Yoon Lee
Vice
President Research
|
Nil
|
Nil
|
396,579/252,313
|
0/0
|
Mr.
Peter Korth
Former
Chief Financial Officer
|
Nil
|
Nil
|
250,000/0
|
0/0
|
Number of
common shares to be issued upon exercise of outstanding
options
(a)
|
Number of
common shares remaining available for future issuance under the equity
compensation plans (Excluding Securities reflected
in Column (a))
(c)
|
Total
Stock Options outstanding and available for Grant
(a) + (c)
|
|||||
Plan Category
|
Number
|
% of common shares
outstanding
|
Weighted-average
exercise
price of
outstanding
options
(b)
|
Number
|
% of common shares
outstanding
|
Number
|
% of
Common
shares
outstanding
|
Equity
compensation plans approved by Shareholders
|
16,438,000
|
7.6
|
$0.45
|
16,209,000
|
7.4
|
32,647,000
|
15%
|
Equity
compensation plans approved by Shareholders
(August 26, 2008)
|
20,475,000
|
8.3
|
$0.38
|
16,628,193(1)
|
6.7
|
37,103,193
|
15%
|
(1)
|
The
Corporation had applied to the TSX to list 5,592,097 of the common shares
available for future issuance under the Corporation's equity compensation
plans.
|
|
EQUITY
COMPENSATION PLANS
|
|
2003
Plan
|
|
•
|
an
amendment to the maximum number of common shares reserved for issuance
under the 2003 Plan and under any other security based compensation
arrangement of the Corporation;
|
|
•
|
a
reduction in the exercise price for options held by
insiders;
|
|
•
|
an
extension to the term of options held by insiders;
and
|
|
•
|
an
increase in the 10% limits on grants to
insiders.
|
|
Base
Salary - Initial Stock
Options
|
|
Potential
Annual Cash Bonuses and Annual Participation in the 2003 Stock Option
Plan
|
|
President
and Chief Executive Officer
Compensation
|
|
•
|
maximize
the value of LOR-2040 in Acute Myeloid Leukemia through the timely
enrollment of patients in the ongoing Phase II clinical trial and
preparation of a Phase III study
proposal;
|
|
•
|
maximize
the value of LOR-2040 in MDS through the preparation of a development plan
and submission of a orphan drug application to certain regulatory
bodies;
|
|
•
|
maximize
the value of LOR-253 through the completion of certain pre-clinical
objectives and drafting of a Phase I protocol for advisory
review;
|
|
•
|
establishing
at least two partnerships (one academic and one
corporate);
|
|
•
|
evaluate
and assess potential merger and/or acquisition candidates;
and
|
|
•
|
certain
other objectives.
|
|
PERFORMANCE
GRAPH
|
Year End
|
2003
|
2004
|
2005
|
2006
|
2007
|
2008
|
||||||||||||||||||
LOR
|
$ | 100 | $ | 67 | $ | 56 | $ | 28 | $ | 20 | $ | 12 | ||||||||||||
S&P/TSX
Composite Index
|
$ | 100 | $ | 122 | $ | 140 | $ | 171 | $ | 205 | $ | 215 |
Year End
|
31-May-03
|
31-May-04
|
31-May-05
|
31-May-06
|
31-May-07
|
31-May-08
|
|||||||||||||||
LOR
|
100=$1.26
|
$ | 0.84 | $ | 0.71 | $ | 0.35 | $ | 0.25 | $ | 0.15 | ||||||||||
S&P/TSX
Composite Index
|
100=6,860
|
8,347 | 9,619 | 11,744 | 14,082 | 14,715 |
Director
|
Independent
|
Herbert
Abramson
|
Yes
|
J.
Kevin Buchi(1)
|
Yes
|
Denis
Burger
|
Yes
|
Susan
Koppy(1)
|
Yes
|
Georg
Ludwig
|
Yes
|
Alan
Steigrod(1)
|
Yes
|
Mark
Vincent
|
Yes
|
Jim
A. Wright
|
No
|
Aiping
Young
|
No
|
(1)
|
Not
standing for re-election at the current shareholder
meeting
|
Director
|
Reporting Issuer
|
||
Herbert
Abramson
|
St
Andrew Goldfields Ltd.
|
||
J.
Kevin Buchi(1)
|
-
|
||
Denis
Burger
|
Trinity
Biotech plc
Paulson
Capital
|
||
Susan
Koppy(1)
|
-
|
||
Georg
Ludwig
|
-
|
||
Alan
Steigrod(1)
|
Sepracor
Inc.
|
||
Mark
Vincent
|
-
|
||
Jim
A. Wright
|
-
|
||
Aiping
Young
|
-
|
(1)
|
Not
standing for re-election at the current shareholder
meeting
|
Director
|
Meetings Attended
|
Herbert
Abramson(2)
|
8
of 8
|
J.
Kevin Buchi(1)
|
8
of 9
|
Denis
Burger(3)
|
5
of 6
|
Susan
Koppy(3)
(1)
|
6
of 6
|
Georg
Ludwig
|
8
of 9
|
Alan
Steigrod(1)
|
8
of 9
|
Mark
Vincent(3)
|
6
of 6
|
Jim
A. Wright
|
8
of 9
|
Aiping
Young
|
9
of 9
|
(1)
|
Not
standing for re-election at the current shareholder
meeting
|
(2)
|
Appointed
to the Board July 23, 2007
|
(3)
|
Elected
to the Board September 19, 2007
|
1.
|
A
majority of the directors of the Board will be independent as defined by
NI 58-101, U.S. securities laws and applicable stock exchange rules. The
Board will have no more than the maximum set out in the Corporation’s
articles and by-laws, which maximum number the Board will reassess from
time to time having consideration for the particular needs of the
Corporation.
|
2.
|
Appointments
to the Board will be reviewed on an annual basis. The Corporate Governance
and Nominating Committee, in consultation with the CEO, is responsible for
identifying and recommending new nominees with appropriate skills to the
Board.
|
3.
|
The
chair of the Board (the "Chair") will be an
independent director and will be appointed by a vote of the Board on an
annual basis.
|
4.
|
The
Board will report to the shareholders of the
Corporation.
|
1.
|
The
Board will meet as required, but at least once
quarterly.
|
2.
|
The
independent directors will meet as required, without the non-independent
directors and members of management, but at least once
quarterly.
|
3.
|
In
connection with each meeting of the Board and each meeting of a committee
of the Board of which a director is a member, each director
will:
|
|
(a)
|
review
thoroughly the materials provided to the directors in connection with the
meeting and be adequately prepared for the meeting;
and
|
|
(b)
|
attend
each meeting in person, by phone or by video-conference depending on the
format of the meeting, to the extent
practicable.
|
4.
|
The
Board will:
|
|
(a)
|
adopt
a strategic planning process and approve a strategic plan each year;
and
|
|
(b)
|
approve
and monitor the operational plans and budgets of the Corporation submitted
by management at the beginning of each fiscal
year.
|
|
In
establishing corporate performance objectives, the Board
will:
|
|
(a)
|
ensure
that it has adequate opportunity and information available to it to gain
knowledge of the business and the industry sufficient to make fully
informed decisions and to adopt meaningful and realistic long-term and
short-term strategic objectives for the Corporation. This may include the
opportunity for the Board to meet from time to time with industry, medical
and scientific experts in related fields of
interest;
|
|
(b)
|
ensure
that effective policies and processes are in place relating to the proper
conduct of the business, the effective management of risk and the values
to be adopted by the Corporation;
and
|
|
(c)
|
ensure
that appropriate and effective environmental and occupational health and
safety policies are in place, are operational and are supported by
adequate resources.
|
5.
|
The
Board will:
|
|
(a)
|
ensure
the integrity of the Corporation's financial reporting and internal
control and disclosure policies and
processes;
|
|
(b)
|
review
the Corporation's quarterly and year-end audited financial
statements;
|
|
(c)
|
review
annual audit plans and findings and monitor the implementation of audit
recommendations; and
|
|
(d)
|
ensure
that the Board has available to it any independent external advice that
may be required from time to time.
|
|
(e)
|
(e)
implement, or delegate the implementation of measures for receiving
feedback from stakeholders.
|
6.
|
The
Board will:
|
|
(a)
|
ensure
that the business of the Corporation is conducted in compliance with
applicable laws and regulations and according to the highest ethical
standards;
|
|
(b)
|
identify
and document the financial risks and other risks that the Corporation
faces in the course of its business and ensure that such risks are
appropriately managed; and
|
|
(c)
|
adopt
a disclosure policy.
|
7.
|
The
Board will ensure that effective communication and disclosure policies are
in place between the Board and the Corporation's shareholders, other
stakeholders and the public. The Board will determine, from time to time,
the appropriate criteria against which to evaluate performance against
shareholder expectations and will set corporate strategic goals and
objectives within this context. The Board will regularly review its
criteria for the evaluation of shareholder expectations to ensure that
they remain relevant to changing
circumstances.
|
8.
|
The
Board will:
|
|
(a)
|
to
the extent feasible, satisfy itself as to the integrity of the CEO and
other executive officers and that all such officers are creating a culture
of integrity throughout the
Corporation;
|
|
(b)
|
ensure
that the CEO is appropriately managing the business of the
Corporation;
|
|
(c)
|
ensure
appropriate succession planning is in place (including appointing,
training and monitoring senior management), in particular with respect to
the CEO position;
|
|
(d)
|
establish
corporate objectives for the CEO annually and evaluate the performance of
the CEO against these corporate
objectives;
|
|
(e)
|
consider
and approve major business initiatives and corporate transactions proposed
by management; and
|
|
(f)
|
ensure
the Corporation has internal control and management information systems in
place.
|
9.
|
The
Board will:
|
|
(a)
|
ensure
that an appropriate governance structure is in place, including a proper
delineation of roles and clear authority and accountability among the
Board, Board committees, the CEO, the Chief Financial Officer (or its
functional equivalent) and the Chief Operating
Officer;
|
|
(b)
|
develop
a process for the orientation and education of new members of the
Board;
|
|
(c)
|
support
continuing education opportunities for all members of the
Board;
|
|
(d)
|
in
conjunction with the Corporate Governance and Nominating Committee, assess
the participation, contributions and effectiveness of the Chair, and
individual Board members on an annual
basis;
|
|
(e)
|
monitor
the effectiveness of the Board and its committees and the actions of the
Board as viewed by the individual directors and senior
management;
|
|
(f)
|
ensure
that Board meetings operate effectively, agendas are focused on the
governance role of the Board, and that the Board is able to function
independently of management when
required;
|
|
(g)
|
ensure
that effective governance policies are in place regarding the conduct of
individual directors and employees, including but not limited to, policies
relating to insider trading and confidentiality and conflict of
interest;
|
|
(h)
|
establish
the committees of the Board it deems necessary or as required by
applicable law to assist it in the fulfillment of its mandate;
and
|
|
(i)
|
disclose
on an annual basis the mandate, composition of the Board and its
committees.
|